Targets › CD74
2 programs from 2 companies in 6 trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2027.
Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. Serves as cell surface receptor for the cytokine MIF.; FUNCTION:…. (UniProt, P04233)
Open in Phaseline: the race on CD74, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Repotrectinib Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | NTRK1, NTRK2, ROS1, NTRK3, CD74 | Phase 3 | Carcinoma, Non-Small-Cell Lung | Feb 2027 |
| Turning Point Therapeutics | Repotrectinib (TPX-0005) Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | NTRK1, NTRK2, ROS1, NTRK3, CD74 | Phase 1 | Locally Advanced Solid Tumors; NSCLC; NSCLC Stage IV; Advanced Cancer | Sep 2027 |
Locally Advanced Solid Tumors (2) NSCLC (1) NSCLC Stage IV (1) Advanced Cancer (1) Carcinoma, Non-Small-Cell Lung (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.